International Journal of Infection

Published by: Kowsar

Risk Factors and Pattern of Changes in Liver Enzymes Among the Patients With Anti-Tuberculosis Drug-Induced Hepatitis

Maliheh Metanat 1 , Batool Sharifi Mood 1 , * , Masoud Salehi 1 , Mohammad Rakhshani 1 and Saeideh Metanat 1
Authors Information
1 Infectious Diseases and Tropical Medicine Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran
Article information
  • International Journal of Infection: April 30, 2015, 2 (2); e25753
  • Published Online: April 20, 2015
  • Article Type: Research Article
  • Received: December 1, 2014
  • Revised: December 5, 2014
  • Accepted: December 21, 2014
  • DOI: 10.17795/iji-25753

To Cite: Metanat M, Sharifi Mood B, Salehi M, Rakhshani M, Metanat S. Risk Factors and Pattern of Changes in Liver Enzymes Among the Patients With Anti-Tuberculosis Drug-Induced Hepatitis, Int J Infect. 2015 ; 2(2):e25753. doi: 10.17795/iji-25753.

Copyright © 2015, Infectious Diseases and Tropical Medicine Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003; 167(11): 1472-7[DOI][PubMed]
  • 2. Burman WJ, Reves RR. Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers. Am J Respir Crit Care Med. 2001; 164(7): 1112-3[DOI][PubMed]
  • 3. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008; 23(2): 192-202[DOI][PubMed]
  • 4. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002; 22(2): 145-55[DOI][PubMed]
  • 5. Tost JR, Vidal R, Cayla J, Diaz-Cabanela D, Jimenez A, Broquetas JM, et al. Severe hepatotoxicity due to anti-tuberculosis drugs in Spain. Int J Tuberc Lung Dis. 2005; 9(5): 534-40[PubMed]
  • 6. Kiter G, Coskunol I. Hepatotoxicity during the anti-tuberculosis treatment: a retrospective survey of 5-year-period. 2000; 48: 20-5
  • 7. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest. 1991; 99(2): 465-71[PubMed]
  • 8. Sistanizad M, Azizi E, Khalili H, Hajiabdolbaghi M, Gholami K, Mahjub R. Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism. Iran J Pharm Res. 2011; 10(3): 633-9[PubMed]
  • 9. Khalili H, Dashti-Khavidaki S, Rasoolinejad M, Rezaie L, Etminani M. Anti-tuberculosis drugs related hepatotoxicity; incidence, risk factors, pattern of changes in liver enzymes and outcome. J Pharm Sci. 2009; 17(3): 163-7
  • 10. Dossing M, Wilcke JT, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis. 1996; 77(4): 335-40[PubMed]
  • 11. Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 2002; 35(4): 883-9[DOI][PubMed]
  • 12. Shakya R, Rao BS, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother. 2004; 38(6): 1074-9[DOI][PubMed]
  • 13. Teleman MD, Chee CB, Earnest A, Wang YT. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int J Tuberc Lung Dis. 2002; 6(8): 699-705[PubMed]
  • 14. Hwang SJ, Wu JC, Lee CN, Yen FS, Lu CL, Lin TP, et al. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol. 1997; 12(1): 87-91[PubMed]
  • 15. Metanat M, Sharifi-Mood B, Shahreki S, Dawoudi SH. Prevalence of multidrug-resistant and extensively drug-resistant tuberculosis in patients with pulmonary tuberculosis in zahedan, southeastern iran. Iran Red Crescent Med J. 2012; 14(1): 53-5[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments